- Home
- IBRX vs TRMD Comparison
IBRX vs TRMD Comparison
Compare IBRX & TRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- TRMD
- Stock Information
- Founded
- IBRX 2014
- TRMD 1889
- Country
- IBRX United States
- TRMD United Kingdom
- Employees
- IBRX N/A
- TRMD N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- TRMD Marine Transportation
- Sector
- IBRX Health Care
- TRMD Consumer Discretionary
- Exchange
- IBRX Nasdaq
- TRMD Nasdaq
- Market Cap
- IBRX 1.9B
- TRMD 1.9B
- IPO Year
- IBRX N/A
- TRMD N/A
- Fundamental
- Price
- IBRX $2.94
- TRMD $20.39
- Analyst Decision
- IBRX Strong Buy
- TRMD Buy
- Analyst Count
- IBRX 3
- TRMD 1
- Target Price
- IBRX $13.58
- TRMD $48.00
- AVG Volume (30 Days)
- IBRX 6.3M
- TRMD 1.4M
- Earning Date
- IBRX 11-12-2024
- TRMD 03-06-2025
- Dividend Yield
- IBRX N/A
- TRMD 23.54%
- EPS Growth
- IBRX N/A
- TRMD N/A
- EPS
- IBRX N/A
- TRMD 7.70
- Revenue
- IBRX $7,332,000.00
- TRMD $1,641,593,000.00
- Revenue This Year
- IBRX $2,515.60
- TRMD N/A
- Revenue Next Year
- IBRX $766.19
- TRMD N/A
- P/E Ratio
- IBRX N/A
- TRMD $2.77
- Revenue Growth
- IBRX 1218.71
- TRMD 3.90
- 52 Week Low
- IBRX $2.28
- TRMD $17.77
- 52 Week High
- IBRX $10.53
- TRMD $40.47
- Technical
- Relative Strength Index (RSI)
- IBRX 48.30
- TRMD 46.59
- Support Level
- IBRX $2.28
- TRMD $20.53
- Resistance Level
- IBRX $2.54
- TRMD $23.20
- Average True Range (ATR)
- IBRX 0.25
- TRMD 0.70
- MACD
- IBRX 0.10
- TRMD 0.24
- Stochastic Oscillator
- IBRX 64.71
- TRMD 35.25
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Exhaust segment.